Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
At AGBT, Complete Genomics showcases expanded sequencing applications, talks from customers and collaborators on research powered by the DNBSEQ-T7 Sequencer | ||
By: PR Newswire Association LLC. - 06 Feb 2024 | Back to overview list |
|
The genomic sequencing solutions provider also introduces Q40 sequencing quality, announces new DNBSEQ products SAN JOSE, Calif., Feb. 6, 2024 /PRNewswire/ -- Complete Genomics, a California-based life sciences company that provides novel, comprehensive sequencing solutions, today highlighted expanded sequencing applications enabled by DNBSEQ™-T7, a leading high- throughput sequencer which will be the subject of customer talks at the Advances in Genome Biology and Technology (AGBT) General Meeting. After four years in the field, the DNBSEQ-T7, or the T7, remains a leading sequencer in its class, due to its speed, accuracy and flexibility. With four independently operated flow cells, it can accommodate 14-16 genomes per flow cell and sequence up to 64 whole genomes in 24 hours. Coupled with $1.50 per Gigabase pricing, equivalent to a $150 genome, and truly PCR-Free data, the T7 provides a compelling platform for a range of labs. The T7 enables a wide range of applications such as CompleteWGS, a novel phased genome approach, spatial transcriptomics, cf-DNA sequencing for MRD and early detection, and single cell sequencing. Enabling these applications at scale are required to advance biological knowledge and insights. The T7 is an ideal platform to perform large scale, more complex research studies. Standard MPS 2.0 - Improved Q40 sequencing quality on a range of DNBSEQ™ platforms Standard MPS 2.0 is enabled by updated sequencing reagents and software to deliver Q40 data quality, improving overall sequencing performance, and will be initially introduced for select DNBSEQ instruments including T7, DNBSEQ-G99, and DNBSEQ-G400 in 2024. "The Standard MPS 2.0 chemistry demonstrates Complete Genomics' commitment to continuing to advance the core technology to continue to meet the needs of researchers as they pioneer novel ways to utilize sequencing data. We are excited for our customers to experience first-hand the benefits that this solution will enable for their work, "said Rade Drmanac, cofounder and Chief Scientific Officer of Complete Genomics. New product: DNBSEQ™-G800
Now commercially available in the U.S.: DNBSEQ™-T20X2 and DNBSEQ™-E25
About Complete Genomics * For Research Use Only. Not for use in diagnostic procedures. Media Contact SOURCE Complete Genomics |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |